|
IQVIA™ Real-World Insights Bibliography
| Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 |
| Author(s): Janet Sultana 1 2, Salvatore Crisafulli 3, Mariana Almas 4, Ippazio Cosimo Antonazzo 5 6, Esme Baan 7, Claudia Bartolini 6, Maria Paola Bertuccio 3, Fedele Bonifazi 8 9, Annalisa Capuano 10 11, Antonella Didio 8 9, Vera Ehrenstein 12, Mariagrazia Felisi 8 13, Carmen Ferrajolo 10 11, Andrea Fontana 14, Remy Francisca 7, Annie Fourrier-Reglat 15, Joan Fortuny 16, Rosa Gini 6, Giulia Hyeraci 6, Christel Hoeve 7, Christos Kontogiorgis 17, Valentina Isgrò 18, Panagiotis-Nikolaos Lalagkas 17, Luca L'Abbate 18, Deborah Layton 19, Annalisa Landi 8 9, Silvia Narduzzi 19, Leonardo Roque Pereira 20, Georgios Poulentzas 17, Concetta Rafaniello 10 11, Giuseppe Roberto 6, Giulia Scondotto 3, Liberata Sportiello 10 11, Maddalena Toma 8 9, Massoud Toussi 19, Katia Verhamme 7, Elisabetta Volpe 8 9, Gianluca Trifirò 18, |
| Affiliations(s): Pharmacy Department, Mater Dei Hospital, Msida, Malta.
2Exeter College of Medicine and Health, Exeter, UK.
3Department of Medicine, University of Verona, Verona, Italy.
4Real World Solutions Department, IQVIA, Lisbon, Portugal.
5Research Centre on Public Health (CESP), University of Milan-Bicocca, Milan, Italy.
6Agenzia Regionale di Sanità della Toscana, Florence, Italy.
7Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands.
8TEDDY European Network of Excellence for Paediatric Clinical Research, Pavia, Italy.
9Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Bari, Italy.
10Department of Experimental Medicine, University of Campania "Vanvitelli", Naples, Italy.
11Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.
12Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
13CVBF Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy.
14Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
15Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team of Pharmacoepidemiology, UMR 1219, Bordeaux, France.
16RTI Health Solutions, Barcelona, Spain.
17Democritus University of Thrace, Alexandroupolis, Greece.
18Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
19Data Science Hub, Real World Solutions, IQVIA, London, UK.
20Department of Datascience & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands. |
Publication(s): Pharmacoepidemiol Drug Saf
. 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11.
|
| Document Type(s): Article, |
| Countries: Denmark, France, Italy, Netherlands, Portugal, Spain, UK, |
| Click here for the abstract |
C:
Y: |
Drug safety, Drug Utlization Study,
2022 |
|
L:
A: |
English
Database Study, Review, |
|
 |
| |
| |
| The Certainty Framework for Assessing Realâ€World Data in Studies of Medical Product Safety and Effectiveness |
| Author(s): Noelle M. Cocoros Peter Arlett Nancy A. Dreyer Chieko Ishiguro Solomon Iyasu Miriam Sturkenboom Wei Zhou Sengwee Toh |
| Affiliations(s): 1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
2Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.
3London School of Hygiene and Tropic Medicine, London, UK.
4Center for Advanced Evidence Generation, IQVIA Real World Solutions, Cambridge, Massachusetts, USA.
5Division of Epidemiology, Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
6Center for Observational and Real-world Evidence, Merck & Co., Inc., Kenilworth, New Jersey, USA.
7Julius Center, Global Health, University Medical Center Utrecht, Utrecht, The Netherlands. |
Publication(s): https://doi.org/10.1002/cpt.2045
|
| Document Type(s): Article, |
| Countries: Japan, Netherlands, USA, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes,
2020 |
|
L:
A: |
English
direct to patient research, Real World Data, Real World Evidence, |
|
|
| |
| |
| Cost effectiveness of cladribine tablets for treatment of RRMS in the Netherlands |
| Author(s): de Francesco M1, Mahajan K2, Michels RE3, Schiffers K4, Budhia S5, Harty G6, Krol M3 |
| Affiliations(s): 1IQVIA, Zaventem, Belgium,
2IQVIA, Gurgaon, India,
3IQVIA, Amsterdam, The Netherlands,
4Merck B.V., an affiliate of Merck KGaA, Schiphol-Rijk, The Netherlands, 5PAREXEL International, Waltham, MA, USA,
6EMD Serono, Billerica, MA, USA |
Publication(s): 2018-11, ISPOR Europe 2018, Barcelona, Spain
|
| Document Type(s): Article, |
| Countries: Netherlands, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2019 |
|
L:
A: |
English
Cost effectiveness, Predictive analytics, |
|
|
| |
| |
| Dutch health state utilities for infertility and subfertility. |
| Author(s): Krol M, Nap A, Michels RM, Veraart CPWM, Goossens LMA |
| Affiliations(s): IQVIA, Netherlands |
Publication(s): ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
|
| Document Type(s): Abstract, |
| Countries: Netherlands, |
C:
Y: |
Health economics, Health status & patient reported outcomes,
2018 |
|
L:
A: |
English
Quality of life, Utility analysis, |
|
|
| |
| |
| Cost effectiveness of cladribine tablets for treatmetn of RMS in The Netherlands. |
| Author(s): De Francesco M1, Mahajan K2, Michels R3, Schiffers K4, Budhia S5, Harty G5, Krol M3 |
| Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, India Michels 3 IQVIA, Netherlands 4 Merck, Netherlands 5 Merck, UK |
Publication(s): ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
|
| Document Type(s): Abstract, |
| Countries: Netherlands, |
C:
Y: |
Neurological disorders,
2018 |
|
L:
A: |
English
Cost effectiveness, Cost utility, |
|
|
| |
| |
| Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. |
| Author(s): Buijs S1, Krol M2, de Voer G3 |
| Affiliations(s): 1 Healthcare Insights, Netherlands 2 IQVIA, Netherlands 3 Merck, Netherlands |
Publication(s): Journal of Comparative Effectiveness Research, 2018, Vol. 7, No. 5
|
| Document Type(s): Article, |
| Countries: Netherlands, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2018 |
|
L:
A: |
English
Cost of illness, |
|
|
| |
| |
| TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES |
| Author(s): Norrbacka K, Divino V, Boye K, Lebrec J, Dekoven M |
| Affiliations(s): Eli Lilly, IQVIA |
Publication(s): ISPOR Europe 2018
|
| Document Type(s): Poster, |
| Countries: Belgium, Canada, France, Germany, Italy, Netherlands, |
| Click here for the abstract |
C:
Y: |
Diabetes,
2018 |
|
L:
A: |
English
Retrospective database analysis, |
|
|
| |
| |
| Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis |
| Author(s): Marieke Krol1, Gert de Voer2, Ulrike Osowski3 |
| Affiliations(s): 1QuintilesIMS, Capelle aan den Ijssel, the Netherlands; 2Merck B.V., Schiphol-Rijk, the Netherlands; 3Merck KGaA, Darmstadt, Germany |
Publication(s): Patient Preference and Adherence 2017:11 1189–1196
|
| Document Type(s): Article, |
| Countries: Germany, Netherlands, |
C:
Y: |
Gastrointestinal disorders,
2017 |
|
L:
A: |
English
Retrospective cohort analysis, Retrospective database analysis, |
|
|
| |
| |
| Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model |
| Author(s): Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7 |
| Affiliations(s): 1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany |
Publication(s): JHEOR 2017;5(1):89-108
|
| Document Type(s): Article, |
| Countries: Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK, |
C:
Y: |
Immunology and Vaccination, Infectious disease, Respiratory disease,
2017 |
|
L:
A: |
English
Epidemiological study, Public Health, |
|
|
| |
| |
| Patient adherence to subcutaneous IFN beta-1a injections using the Rebismart® injection device:a retrospective real-world among Dutch and German patients with multiple sclerosis. |
| Author(s): Krol M1, deVoer G2, Osowski U3 |
| Affiliations(s): 1 QuintilesIMS, The Netherlands 2 Merck B.V., Schiphol-Rijk, the Netherlands 3 Merck KGaA, Darmstadt, Germany |
| Publication(s): |
| Document Type(s): Article, |
| Countries: Germany, Netherlands, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2017 |
|
L:
A: |
English
clinical setting: Secondary care, Compliance, Retrospective database analysis, |
|
|
| |
| |
 1 of 6 
|
|
